
ACTU Stock Forecast & Price Target
ACTU Analyst Ratings
Bulls say
Actuate Therapeutics Inc's development of elraglusib has shown significant clinical promise, as evidenced by improved median overall survival and one-year survival rates in patients with metastatic pancreatic adenocarcinoma, compared to existing treatments. The company has bolstered its financial position through a recent funding round, allowing it to explore various regulatory pathways and support upcoming clinical trials that may underline the efficacy of elraglusib. With substantial resources now available, Actuate is well-positioned to advance its research and operational capabilities, which could lead to positive regulatory outcomes in the near future.
Bears say
Actuate Therapeutics Inc is facing financial challenges characterized by a significant cash burn rate that raises concerns about its ability to fund ongoing development programs for elraglusib and other pipeline candidates. Additionally, the company has reported disappointing clinical trial results, which may hinder regulatory approval and market entry, thereby limiting potential revenue generation. Furthermore, the competitive landscape in cancer therapeutics poses a risk, as established players may outpace Actuate Therapeutics in delivering effective treatment solutions, impacting investor confidence and stock performance.
This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares